government regulation

Summary

Summary: Exercise of governmental authority to control conduct.

Top Publications

  1. doi Evaluation of carcinogenic hazard of diesel engine exhaust needs to consider revolutionary changes in diesel technology
    Roger O McClellan
    Toxicology and Risk Analysis, 13701 Quaking Aspen Place NE, Albuquerque, NM 87111, USA
    Regul Toxicol Pharmacol 63:225-58. 2012
  2. pmc Scientific and legal perspectives on science generated for regulatory activities
    Carol J Henry
    American Chemistry Council, Arlington, Virginia, USA
    Environ Health Perspect 116:136-41. 2008
  3. ncbi Lead exposure, lead poisoning, and lead regulatory standards in China, 1990-2005
    Xibiao Ye
    Fudan University School of Public Health, Shanghai, China
    Regul Toxicol Pharmacol 46:157-62. 2006
  4. ncbi Informed consent, anticipatory regulation and ethnographic practice
    Elizabeth Murphy
    University of Nottingham, Nottingham, UK
    Soc Sci Med 65:2223-34. 2007
  5. doi Tobacco: a product like any other?
    Kirill Danishevskiy
    ATACA Anti Tobacco Advocacy Coalition, Moscow, Russia
    Health Econ Policy Law 6:265-72. 2011
  6. ncbi FDA regulation of stem-cell-based therapies
    Dina Gould Halme
    School of Medicine, University of California at San Francisco, San Francisco, USA
    N Engl J Med 355:1730-5. 2006
  7. ncbi Ambient air pollution: health hazards to children
    Janice J Kim
    Pediatrics 114:1699-707. 2004
  8. ncbi A legal framework for preventing cardiovascular diseases
    Wendy C Perdue
    Georgetown University Law Center, Washington, DC 20001, USA
    Am J Prev Med 29:139-45. 2005
  9. pmc Drug shop regulation and malaria treatment in Tanzania--why do shops break the rules, and does it matter?
    Catherine Goodman
    Health Policy Unit, London School of Hygiene and Tropical Medicine, London, UK
    Health Policy Plan 22:393-403. 2007
  10. doi Why do people cooperate with medical research? Findings from three studies
    Mary Dixon-Woods
    University of Leicester, Leicester, United Kingdom
    Soc Sci Med 68:2215-22. 2009

Detail Information

Publications237 found, 100 shown here

  1. doi Evaluation of carcinogenic hazard of diesel engine exhaust needs to consider revolutionary changes in diesel technology
    Roger O McClellan
    Toxicology and Risk Analysis, 13701 Quaking Aspen Place NE, Albuquerque, NM 87111, USA
    Regul Toxicol Pharmacol 63:225-58. 2012
    ..We recommend that future reviews of carcinogenic hazards of diesel exhaust evaluate NTDE separately from TDE...
  2. pmc Scientific and legal perspectives on science generated for regulatory activities
    Carol J Henry
    American Chemistry Council, Arlington, Virginia, USA
    Environ Health Perspect 116:136-41. 2008
    ..In a closely related example, the U.S. Environmental Protection Agency considered but abandoned a program to implement standards aimed at "external" information...
  3. ncbi Lead exposure, lead poisoning, and lead regulatory standards in China, 1990-2005
    Xibiao Ye
    Fudan University School of Public Health, Shanghai, China
    Regul Toxicol Pharmacol 46:157-62. 2006
    ..The 2002 Act, without the necessary enforcement, did not appear to have a major impact on either lead exposures or lead poisoning in China. Much work in enforcing the 2002 Act remains to be done...
  4. ncbi Informed consent, anticipatory regulation and ethnographic practice
    Elizabeth Murphy
    University of Nottingham, Nottingham, UK
    Soc Sci Med 65:2223-34. 2007
    ..We conclude the paper with a number of suggestions about how such professional models might be implemented...
  5. doi Tobacco: a product like any other?
    Kirill Danishevskiy
    ATACA Anti Tobacco Advocacy Coalition, Moscow, Russia
    Health Econ Policy Law 6:265-72. 2011
    ..We argue that the only way to redress this situation is to recognize that tobacco production and sales must be regulated in the same way as any other harmful and addictive substance...
  6. ncbi FDA regulation of stem-cell-based therapies
    Dina Gould Halme
    School of Medicine, University of California at San Francisco, San Francisco, USA
    N Engl J Med 355:1730-5. 2006
  7. ncbi Ambient air pollution: health hazards to children
    Janice J Kim
    Pediatrics 114:1699-707. 2004
    ....
  8. ncbi A legal framework for preventing cardiovascular diseases
    Wendy C Perdue
    Georgetown University Law Center, Washington, DC 20001, USA
    Am J Prev Med 29:139-45. 2005
    ..Examples of key roles that health professionals can play in advancing such an understanding are presented...
  9. pmc Drug shop regulation and malaria treatment in Tanzania--why do shops break the rules, and does it matter?
    Catherine Goodman
    Health Policy Unit, London School of Hygiene and Tropical Medicine, London, UK
    Health Policy Plan 22:393-403. 2007
    ..Such a change in approach has the potential to provide a firmer platform for public-private collaboration to improve shop-based treatment...
  10. doi Why do people cooperate with medical research? Findings from three studies
    Mary Dixon-Woods
    University of Leicester, Leicester, United Kingdom
    Soc Sci Med 68:2215-22. 2009
    ..Attention to the institutional context of research is critical to understanding what makes cooperation possible, and has important implications for the design of regulatory regimes for research...
  11. pmc Understanding Philip Morris's pursuit of US government regulation of tobacco
    P A McDaniel
    Center for Tobacco Control Research and Education, University of California, San Francisco, 530 Parnassus Avenue, Suite 366, San Francisco, CA 94143 1390, USA
    Tob Control 14:193-200. 2005
    ..To investigate Philip Morris's support of US Food and Drug Administration (FDA) regulation of tobacco products and analyse its relationship to the company's image enhancement strategies...
  12. ncbi Commercialism, choice and consumer protection: regulation of complementary medicines in Australia
    Ken J Harvey
    School of Public Health, La Trobe University, Melbourne, Vic, Australia
    Med J Aust 188:21-5. 2008
    ..Complaint procedures (now overloaded) are no substitute for adequate regulation at the time of market entry. Regulatory reform of listed and homoeopathic products is required...
  13. pmc The interplay of public health law and industry self-regulation: the case of sugar-sweetened beverage sales in schools
    Michelle M Mello
    Department of Health Policy and Management, Harvard School of Public Health, 677 Huntington Ave, Boston, MA 02115, USA
    Am J Public Health 98:595-604. 2008
    ....
  14. ncbi Choosing health? First choose your philosophy
    Martin McKee
    Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, London WC1E 7 hT, UK
    Lancet 365:369-71. 2005
  15. pmc The creation of industry front groups: the tobacco industry and "get government off our back"
    Dorie E Apollonio
    Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA 94143, USA
    Am J Public Health 97:419-27. 2007
    ..Those who seek to establish measures to protect public health should be prepared to counter the argument that government should not regulate private behavior...
  16. doi Calorie labeling and food choices: a first look at the effects on low-income people in New York City
    Brian Elbel
    Division of General Internal Medicine at New York University School of Medicine and NYU Wagner School of Public Service, New York City, USA
    Health Aff (Millwood) 28:w1110-21. 2009
    ..However, we did not detect a change in calories purchased after the introduction of calorie labeling. We encourage more research on menu labeling and greater attention to evaluating and implementing other obesity-related policies...
  17. pmc Tobacco industry manipulation of research
    Lisa A Bero
    Department of Clinical Pharmacy, School of Pharmacy, Institute for Health Policy Studies, University of California, San Francisco 94143, USA
    Public Health Rep 120:200-8. 2005
  18. doi Naturally occurring asbestos: a recurring public policy challenge
    R J Lee
    RJ Lee Group Inc, Monroeville, PA 15146, USA
    J Hazard Mater 153:1-21. 2008
    ....
  19. doi Government regulation of sex and sexuality: in their own words
    Sofia Gruskin
    Department of Global Health and Population, Harvard School of Public Health, Boston, MA, USA
    Reprod Health Matters 17:108-18. 2009
    ....
  20. ncbi The health benefits of reduced tropospheric ozone in California
    Bart D Ostro
    Office of Environmental Health Hazard Assessment, California Environmental Protection Agency, Oakland, CA 94612, USA
    J Air Waste Manag Assoc 56:1007-21. 2006
    ....
  21. doi Decline in hospitalisations due to dog bite injuries in Catalonia, 1997-2008. An effect of government regulation?
    Joan R Villalbí
    Agència de Salut Pública de Barcelona, Barcelona, Spain
    Inj Prev 16:408-10. 2010
    ..To analyse population-based data on hospitalisation caused by dog bite injuries after changes in legal regulations on dog ownership, including breed-specific regulations...
  22. ncbi Learning the value of drugs--is rofecoxib a regulatory success story?
    Rebecca S Eisenberg
    University of Michigan Law School, Ann Arbor, USA
    N Engl J Med 352:1285-7. 2005
  23. ncbi Modern regulatory impact analysis: the experience of the European Union
    Bruce Ballantine
    Business Decisions Limited, Heronswood House, Maidstone Road, Pembury, Kent TN2 4DD, UK
    Regul Toxicol Pharmacol 44:57-68. 2006
    ..The paper finally draws a number of conclusions and makes a number of recommendations for further improvements in the quality of the regulatory process in the European Union...
  24. ncbi The birth of the e-clinic. Continuity or transformation in the UK governance of pharmaceutical consumption?
    Nick Fox
    ScHARR, University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK
    Soc Sci Med 61:1474-84. 2005
    ..This continuity can be explained by Rosenau's (Along the Domestic-Foreign Frontier. Cambridge University Press, Cambridge, 1997) model of a contested and fragmenting process of technology governance...
  25. ncbi Manufacturing uncertainty: contested science and the protection of the public's health and environment
    David Michaels
    Department of Environmental and Occupational Health, George Washington University School of Public Health and Health Services, 2100 M St NW, Suite 203, Washington, DC 20037, USA
    Am J Public Health 95:S39-48. 2005
    ..The public health system must ensure that scientific evidence is evaluated in a manner that assures the public's health and environment will be adequately protected...
  26. ncbi Regulatory parallels to Daubert: stakeholder influence, "sound science," and the delayed adoption of health-protective standards
    Roni A Neff
    Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Room E6636, Baltimore, MD 21205, USA
    Am J Public Health 95:S81-91. 2005
    ..Most recently, political tampering with science provides the foundation for some policymakers to disregard science completely in the environmental regulatory process...
  27. ncbi Organophosphate exposures in the United States: a longitudinal analysis of incidents reported to poison centers
    Daniel L Sudakin
    Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, Oregon 97331 6502, USA
    J Toxicol Environ Health A 70:141-7. 2007
    ..The results of this investigation are consistent with other studies that have reported that regulatory restriction of access to pesticide formulations may have a significant impact on the number of human exposure incidents...
  28. ncbi Environmental pediatrics and its impact on government health policy
    Lynn Goldman
    Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 20815, USA
    Pediatrics 113:1146-57. 2004
    ..More recently, these issues have been taken up by states and in the international arena...
  29. ncbi European Clinical Trials Directive: responses made to MHRA consultation letter MLX 287
    David J Flavell
    Lancet 362:1415. 2003
  30. doi Perspectives on human stem cell research
    Kyu Won Jung
    Law School, Hanyang University, 17 Haengdang dong, Seongdong Gu, Seoul 133 791, South Korea
    J Cell Physiol 220:535-7. 2009
    ..We do not need to exclude any type of stem cell research because each has its own merits and issues, and they can facilitate the scientific revolution when working together...
  31. doi Perceived justice and popular support for public health laws: a case study around comprehensive smoke-free legislation in Mexico City
    James F Thrasher
    Department of Health Promotion, Education and Behavior, Arnold School of Public Health, University of South Carolina, Columbia, SC 29208, USA
    Soc Sci Med 70:787-93. 2010
    ....
  32. pmc The unintended consequences of clinical trials regulations
    Alex D McMahon
    Dental School, Faculty of Medicine, University of Glasgow, Glasgow, Scotland
    PLoS Med 3:e1000131. 2009
    ..Alex McMahon and colleagues critique the International Conference on Harmonisation (ICH) guidance on good clinical practice (GCP), arguing that it is having a disastrous effect on noncommerical randomized clinical trials in Europe...
  33. ncbi Legislating "sound science": the role of the tobacco industry
    Annamaria Baba
    Department of Clinical Pharmacy, University of California, San Francisco, 3333 California Street, Suite 420, Box 0613, San Francisco, CA 94143, USA
    Am J Public Health 95:S20-7. 2005
    ..The tobacco industry played a role in establishing laws that increase corporate influence on public health and regulatory policy decisions...
  34. doi Medicine prices in urban Mozambique: a public health and economic study of pharmaceutical markets and price determinants in low-income settings
    Giuliano Russo
    Instituto de Higiene e Medicina Tropical, Rua da Junqueira 96, 1349 008 Lisbon, Portugal
    Health Policy Plan 25:70-84. 2010
    ..We also argue that price controls may not be the most effective way to influence access to medicines in low-income countries, and managing demand and supply towards cheaper effective drugs appears a more suitable policy option...
  35. pmc Child care as an untapped setting for obesity prevention: state child care licensing regulations related to nutrition, physical activity, and media use for preschool-aged children in the United States
    Karen M Kaphingst
    Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, 1300 S 2nd St, Ste 300, Minneapolis, MN 55454, USA
    Prev Chronic Dis 6:A11. 2009
    ..6 million preschool-aged children participated in child care in 2001. Each US state creates and enforces its own child care licensing regulations. We analyzed obesity-related child care licensing regulations of US states...
  36. ncbi Declining sex ratio: role of society, technology and government regulation in Faridabad district, Haryana
    A Bardia
    Centre for Community Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
    Natl Med J India 17:207-11. 2004
    ..a male child, awareness and acceptability of the practice of sex determination), technology (availability and affordability) and government regulation in the adverse ratio for girls in the Ballabgarh block of Haryana in northern India.
  37. ncbi A regulatory patchwork--human ES cell research oversight
    Lori P Knowles
    Health Law Institute, University of Alberta, Canada
    Nat Biotechnol 22:157-63. 2004
  38. pmc Unregulated private markets for health care in Canada? Rules of professional misconduct, physician kickbacks and physician self-referral
    Sujit Choudhry
    Faculty of Law, University of Toronto, ON
    CMAJ 170:1115-8. 2004
  39. ncbi Ethics and policy perspectives on personalized medicine in the post-genomic era
    Melissa R Landon
    Boston University, USA
    J Biolaw Bus 8:28-36. 2005
    ....
  40. ncbi Philip Morris' FDA gambit: good for public health?
    Michael Givel
    Department of Political Science, The University of Oklahoma, 455 West Lindsey, Room 2I7, Norman, USA
    J Public Health Policy 26:450-68. 2005
    ..On the other hand, tobacco products would have remained a politically and economically viable and legal product consumed by millions of Americans many of whom would have continued to suffer from tobacco-related illnesses and deaths...
  41. ncbi Human research protections: time for regulatory reform?
    Karen J Maschke
    Hastings Cent Rep 38:19-22. 2008
  42. doi The first pharmacoepidemiologic investigations: national drug safety policy in the United States, 1901-1902
    David E Lilienfeld
    Perspect Biol Med 51:188-98. 2008
    ..That power, welcomed by manufacturers to restore the public's trust in their products, was enhanced in the 1906 Food and Drug Act, which created the Food and Drug Administration...
  43. ncbi The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly
    David C Vladeck
    Georgetown University Law Center Center of Health Regulation and Governance of the O Neill Institute for National and Global Health Law Institute for Public Representation and Center for Progressive Reform, USA
    Cornell Law Rev 93:981-1002. 2008
  44. pmc Daubert's menace
    Gio Batta Gori
    Am J Public Health 96:206; discussion 206-7. 2006
  45. ncbi New federal guidelines for physician-pharmaceutical industry relations: the politics of policy formation
    Susan Chimonas
    Center on Medicine as a Profession CMAP, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Health Aff (Millwood) 24:949-60. 2005
    ..We also explore the implications--some intended, others unanticipated--of the final document...
  46. ncbi The impact of the cox-2 inhibitor issue on perceptions of the pharmaceutical industry: content analysis and communication implications
    Ragnar E Lofstedt
    King s Centre for Risk Management, King s College London, London, England
    J Health Commun 12:471-91. 2007
    ....
  47. ncbi Quantifying the federal minimal risk standard: implications for pediatric research without a prospect of direct benefit
    David Wendler
    Department of Clinical Bioethics, NIH Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    JAMA 294:826-32. 2005
    ..These data also raise the question of whether the federal minimal risk standard may sometimes fail to provide sufficient protection for children, prompting the need to consider alternative standards...
  48. ncbi The perils of relying on interested parties to evaluate scientific quality
    Wendy Wagner
    University of Texas School of Law, 727 East Dean Keeton Street, Austin, TX 78705 3299, USA
    Am J Public Health 95:S99-106. 2005
    ....
  49. ncbi Neoliberal and public health effects of failing to adopt OSHA's national secondhand tobacco smoke rule
    Michael Givel
    Department of Political Science, The University of Oklahoma, Norman 73109, USA
    Int J Health Serv 36:137-55. 2006
    ....
  50. ncbi Rights, patents, markets and the global AIDS pandemic
    James Thuo Gathii
    Albany Law School, USA
    Fla J Int Law 14:261-352. 2002
  51. ncbi From Asilomar to industrial biotechnology: risks, reductionism and regulation
    Sheldon Krimsky
    Department of Urban and Environmental Policy and Planning, Tufts University, Medford, MA 02155, USA
    Sci Cult (Lond) 14:309-23. 2005
  52. ncbi Legal developments relevant to FDA authority
    Daniel Meron
    Department of Health and Human Services, USA
    Food Drug Law J 62:441-4. 2007
  53. ncbi The case for preemption of prescription drug failure-to-warn claims
    Christine H Kim
    Food Drug Law J 62:399-422. 2007
  54. ncbi Diversionary reframing of the Great Lakes Water Quality Agreement
    Michael Gilbertson
    Occupational and Environmental Health Research Group, Stirling University, Scotland, UK
    J Public Health Policy 28:201-15. 2007
    ..The scientific evidence of continuing injury to health and property from trans-boundary pollution convinces us that this reframing is an unwarranted diversion from the original intent...
  55. ncbi Drug risks and free speech--can Congress ban consumer drug ads?
    Miriam Shuchman
    N Engl J Med 356:2236-9. 2007
  56. pmc Death at a discount: how the tobacco industry thwarted tobacco control policies in US military commissaries
    Elizabeth A Smith
    Department of Social and Behavioral Sciences, University of California, San Francisco, Box 0612 San Francisco, CA 94143 0612, USA
    Tob Control 16:38-46. 2007
    ..Tobacco use also impairs short-term troop readiness...
  57. ncbi Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate
    Howard L Dorfman
    Bayer HealthCare LLC, West Haven, CT, USA
    Food Drug Law J 61:585-622. 2006
  58. pmc A history of drug advertising: the evolving roles of consumers and consumer protection
    Julie Donohue
    University of Pittsburgh, Graduate School of Public Health, Department of Health Policy and Management, 130 DeSoto Street, Crabtree Hall A613, Pittsburgh, PA 15261, USA
    Milbank Q 84:659-99. 2006
    ....
  59. ncbi Pharmaceutical marketing practices: balancing public health and law enforcement interests; moving beyond regulation-through-litigation
    Christopher D Zalesky
    World Wide Health Care Compliance, Johnson and Johnson, USA
    J Health Law 39:235-64. 2006
    ..This approach borrows lessons learned from the FDA's efficient and effective regulatory and enforcement methods and maintains a careful balance between the interests of patient-beneficiaries, the government and industry...
  60. ncbi Privacy and policy for genetic research
    Judith Wagner DeCew
    Department of Philosophy, Clark University, 950 Main Street, Worcester, MA 01610, USA
    Ethics Inf Technol 6:5-14. 2004
    ....
  61. ncbi The federal preemption debate in pharmaceutical labeling product liability actions
    Jodie M Gross
    Harris Beach PLLC, New York, New York, USA
    Tort Trial Insur Pract Law J 43:35-70. 2007
  62. ncbi Balancing government regulation against access to drugs: address to Seton Hall University School of Law, February 16, 2007
    Daniel Meron
    United States Department of Health and Human Services, USA
    Seton Hall Law Rev 37:929-39. 2007
  63. ncbi Obesity--the new frontier of public health law
    Michelle M Mello
    Department of Health Policy and Management, Harvard School of Public Health, Boston, USA
    N Engl J Med 354:2601-10. 2006
  64. doi Public health. A case study of personalized medicine
    S H Katsanis
    Genetics and Public Policy Center, Berman Institute of Bioethics corrected, The Johns Hopkins University, Washington, DC 20036, USA
    Science 320:53-4. 2008
  65. ncbi The pharmaceutical industry's responsibility for protecting human subjects of clinical trials in developing nations
    Finnuala Kelleher
    Columbia Journal of Law and Social Problems, Columbia University, USA
    Columbia J Law Soc Probl 38:67-106. 2004
    ....
  66. doi Bush tails follow-ons
    Jeff Fox
    Nat Biotechnol 26:366. 2008
  67. ncbi Ten years of judicial gatekeeping under Daubert
    Joe S Cecil
    Federal Judicial Center s Program on Scientific and Technical Evidence, One Columbus Circle, NE, Washington, DC 20002, USA
    Am J Public Health 95:S74-80. 2005
    ..Future research should focus on the pretrial screening of expert testimony and interactions between the attorneys and experts in shaping that testimony...
  68. ncbi The need for FDA regulation of tobacco products
    Edward M Kennedy
    Yale J Health Policy Law Ethics 3:101-8. 2002
  69. ncbi Puppy love: bioterrorism, civil rights, and public health
    George J Annas
    Health Law Department, Boston University School of Public Health, USA
    Fla Law Rev 55:1171-90. 2003
  70. ncbi When terrorism threatens health: how far are limitations on personal and economic liberties justified?
    Lawrence O Gostin
    Georgetown Univesity, Washington, DC, USA
    Fla Law Rev 55:1105-70. 2003
  71. ncbi Nontherapeutic research with children: the virtues and vices of legal uncertainty
    David M Smolin
    Cumberland Law School, Samford University, USA
    Cumberland Law Rev 33:621-45. 2002
  72. ncbi Molecular diagnostics: an FDA perspective
    Ali M Ardekani
    Department of Therapeutic Proteins, CBER, FDA, Bethesda, MD 20892, USA
    Expert Rev Mol Diagn 3:129-40. 2003
    ....
  73. ncbi Senators grill NIH director over restrictions on stem-cell research
    Jeffrey Brainard
    Chron High Educ 49:A25. 2003
  74. ncbi America's other drug problem: how the drug industry distorts medicine and politics
    Arnold S Relman
    Harvard Medical School, USA
    New Repub 227:27-41. 2002
  75. ncbi Dipping into Uncle Sam's pockets: federal funding of stem cell research: is it legal?
    Carly Goldstein
    Boston Univ Public Interest Law J 11:229-59. 2002
  76. ncbi Taking another look at the definition of an embryo: President Bush's criteria and the problematic application of federal regulations to human embryonic stem cells
    Simon B Auerbach
    Emory University School of Law, Atlanta, Georgia, USA
    Emory Law J 51:1557-604. 2002
  77. ncbi Liability for institutional review boards: from regulation to litigation
    David B Resnik
    The Brody School of Medicine at East Carolina University, Greenville, North Carolina, USA
    J Leg Med 25:131-84. 2004
  78. ncbi Triage in the nation's medicine cabinet: the puzzling scarcity of vaccines and other drugs
    Lars Noah
    University of Florida, P O Box 117625, Gainesville, FL 32611 7625, USA
    S C Law Rev 54:371-403. 2002
    ..Otherwise, patients may continue to lose access to important therapeutic products...
  79. ncbi Informed consent and investigational new drug abuses in the U.S. military
    Mary L Cummings
    Systems Engineering, University of Virginia, PO Box 400747, Charlottesville, VA 22904 4747, USA
    Account Res 9:93-103. 2002
    ....
  80. ncbi A comprehensive national policy to stop human cloning: an analysis of the Human Cloning Prohibition Act of 2001 with recommendations for federal and state legislatures
    Shawn E Peterson
    Notre Dame Law School, USA
    Notre Dame J Law Ethics Public Policy 17:217-68. 2003
  81. ncbi Experts warn drug industry, government about weaknesses in drug supply chain
    Donna Young
    Am J Health Syst Pharm 60:2176, 2180, 2184. 2003
  82. ncbi Private wealth and public health: a critique of Richard Epstein's defense of the "old" public health
    William J Novak
    Department of History, University of Chicago, 1126 East 59th Street, Chicago, IL 60637, USA
    Perspect Biol Med 46:S176-98. 2003
    ....
  83. ncbi Children in clinical research: a conflict of moral values
    Vera Hassner Sharav
    The Alliance for Human Research Protection
    Am J Bioeth 3:W-IF 2. 2003
    ....
  84. ncbi Cloning and stem cells--handicapping the political and scientific debates
    George Q Daley
    Whitehead Institute for Biomedical Research, Cambridge, USA
    N Engl J Med 349:211-2. 2003
  85. ncbi Clinical trials face heightened scrutiny as science and commerce appear to merge
    Alvin J Lorman
    Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, USA
    J Biolaw Bus 4:23-32. 2001
    ..The risk of increased government involvement includes criminal prosecution of physicians for failing to follow the rules, as an innovative case in California demonstrates...
  86. ncbi Liberalism, communitarianism, and public health: comments on Lawrence O. Gostin's lecture
    Wendy E Parmet
    Northeastern University, USA
    Fla Law Rev 55:1221-40. 2003
  87. ncbi A postmodernist take on the human embryo research debate
    Lars Noah
    University of Florida, USA
    Conn Law Rev 36:1133-61. 2004
  88. ncbi Reflections of a forensic psychiatrist in Washington: politics and policy
    Renee L Binder
    Psychiatry and the Law Program, University of California, San Francisco, CA, USA
    J Am Acad Psychiatry Law 32:324-8. 2004
  89. ncbi Law's knowledge: science for justice in legal settings
    Sheila Jasanoff
    John F Kennedy School of Government, School of Public Health, Department of the History of Science, Harvard University, 79 JFK Street, Room L354, Boston, MA, USA
    Am J Public Health 95:S49-58. 2005
    ..The important question for the law is not how judges can best do justice to science, but rather how courts can better render justice under conditions of uncertainty and ignorance...
  90. ncbi A cognitive scientist looks at Daubert
    George P Lakoff
    1203 Dwinelle Hall, University of California at Berkeley, Berkeley, CA 94720 2650, USA
    Am J Public Health 95:S114-20. 2005
    ..Daubert functions in its application as a strategic initiative that significantly moves America in a conservative direction, in the moral and political spheres, as well as in the legal sphere...
  91. ncbi Why Ashcroft is wrong on assisted suicide
    Nelson Lund
    George Mason University School of Law, USA
    Commentary 113:50-5. 2002
  92. ncbi Protecting research subjects--the crisis at Johns Hopkins
    Robert Steinbrook
    N Engl J Med 346:716-20. 2002
  93. ncbi Pharmacogenetics: ethical issues and policy options
    Allen Buchanan
    Department of Philosophy, University of Arizona, Tucson, AZ, USA
    Kennedy Inst Ethics J 12:1-15. 2002
    ..We analyze each of these categories of ethical issues and provide policy approaches for addressing them...
  94. ncbi Ethics, regulation, and biomedical research
    Matthew Weed
    Yale University, USA
    Kennedy Inst Ethics J 14:361-8. 2004
    ....
  95. ncbi Politics, culture, and the lab: public attitudes toward animals and human embryonic stem cells have fostered different research agendas in Britain and the United States
    Anne Marie Borrego
    Chron High Educ 51:A43-5. 2005
  96. ncbi The President's Council on Bioethics: my take on some of its deliberations
    William F May
    Institute for Practical Bioethics and Public Life, University of Virginia, USA
    Perspect Biol Med 48:229-40. 2005
  97. ncbi What has a decade of Daubert wrought?
    Margaret A Berger
    Brooklyn Law School, 250 Joralemon Street, Room 911, Brooklyn, NY 11201, USA
    Am J Public Health 95:S59-65. 2005
    ..expert witnesses? What do we know about Daubert's impact on improving science in the court room? What has been Daubert's effect on access to the courts? Does Daubert further public policy objectives of protecting the public against harm?..
  98. ncbi Bioethical malpractice: risk and responsibilities in human research
    Barbara A Noah
    Health Law and Policy, University of Florida Levin College of Law, P O Box 117629, Gainesville, FL 32611 7629, USA
    J Health Care Law Policy 7:175-241. 2004
  99. ncbi FDA and EMEA pool scientific advice
    Alla Katsnelson
    Nat Biotechnol 22:1490-1. 2004
  100. ncbi Safety in New Zealand's adventure tourism industry: the client accident experience of adventure tourism operators
    T A Bentley
    Centre for Tourism Research, Department of Management and International Business, Massey University, Albany, New Zealand
    J Travel Med 7:239-45. 2000
    ..CONCLUSIONS: The prevalence of client injuries in activity sectors not presently covered by government regulation, suggests policy makers should look again at extending codes of practice to a wider range of adventure ..
  101. pmc Creating an oversight infrastructure for electronic health record-related patient safety hazards
    Hardeep Singh
    Houston VA Health Services Research and Development Center of Excellence, Texas, USA
    J Patient Saf 7:169-74. 2011
    ..Implementation of this proposed infrastructure can facilitate identification of EHR-related adverse events and errors and potentially create a safer and more effective EHR-based health care delivery system...

Research Grants204 found, 100 shown here

  1. SAFEHAVEN: Decision Support for Nursing Home Resident Disaster Evacuations
    Vincent Mor; Fiscal Year: 2010
    ..Using existing nursing home data from multiple sources, this study seeks to understand the consequences of hurricanes and evacuation decisions, providing the first evidence base to inform the creation of evacuation guidelines. ..
  2. Views and Approaches Toward Research Integrity Among IRBs
    Robert Klitzman; Fiscal Year: 2007
    ..smaller institutions. We anticipate that the data from this study will serve as a significant foundation in assisting future research and the improvement of Rl through guidelines, education and other capacity building. ..
  3. Views of Privacy of Genetic Information
    Robert Klitzman; Fiscal Year: 2005
    ..The findings of this study can enhance further policy, professional and public education, and future research in this area. ..
  4. Impact of Medicare Part D on Racial Disparities in Diabetes Treatment and Outcome
    Julie Marie Donohue; Fiscal Year: 2010
    ....
  5. Innovative Interventions for Smoking Cessation
    Dorothy K Hatsukami; Fiscal Year: 2010
    ..The results of this study will provide useful information on directions to pursue to improve our pharmacotherapies and behavioral treatments and to better understand the various aspects of addiction. ..
  6. TREATMENT OF SMOKELESS TOBACCO USERS
    Dorothy Hatsukami; Fiscal Year: 2005
    ..The results of this study will determine the potential for an alternative and viable method for treating ST users. ..
  7. Novel Determinants and Measures of Smokeless Tobacco Use
    Dorothy K Hatsukami; Fiscal Year: 2010
    ..This study would demonstrate the feasibility and impact of switching ST users to less toxic ST products. Together, these studies will help to guide important policy decisions to reduce the toll of tobacco-related disease. ..
  8. Understanding the Adoption and Implementation of Tobacco-Free Regulation in Subst
    Lillian T Eby; Fiscal Year: 2010
    ..Thus, understanding the additive effects of the implementation of this top-down driven, restrictive, state-mandated regulation on clinicians has substantial individual health and health policy implications. ..
  9. Evaluating Low Ignition Propensity Cigarette Legislation
    RICHARD O CONNOR; Fiscal Year: 2007
    ..Taken together, these studies comprise a comprehensive evaluation of the potential impacts of this harm-reduction policy, which will inform policymakers in other jurisdictions considering similar regulations. ..
  10. TOBACCO EXPOSURE REDUCTION
    Dorothy Hatsukami; Fiscal Year: 2007
    ..The results of research from this TTURC will provide the scientific basis for urgent policy, public education, and regulatory efforts to reduce tobacco harm. ..
  11. Clinical Supervision and Turnover in Substance Abuse Tx
    LILLIAN EBY; Fiscal Year: 2007
    ..This project responds to program announcement PA-03-011 "Services Research in the National Drug Abuse CTN". Substance abuse treatment centers that are affiliated with the Clinical Trails Network will provide data for the project. ..
  12. Clinical Supervision and Turnover in Substance Abuse Tx
    LILLIAN EBY; Fiscal Year: 2009
    ..This project responds to program announcement PA-03-011 "Services Research in the National Drug Abuse CTN". Substance abuse treatment centers that are affiliated with the Clinical Trails Network will provide data for the project. ..
  13. Exploring current smokers? interest in using smokeless tobacco products
    RICHARD O CONNOR; Fiscal Year: 2009
    ..The set of studies may help to tease apart the various aspects of the price-product relationship and so better inform public policy debates. ..
  14. Understanding the Adoption and Implementation of Tobacco-Free Regulation in Subst
    LILLIAN EBY; Fiscal Year: 2009
    ..Thus, understanding the additive effects of the implementation of this top-down driven, restrictive, state-mandated regulation on clinicians has substantial individual health and health policy implications. ..
  15. Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers
    Dorothy K Hatsukami; Fiscal Year: 2010
    ..The results from these studies will help determine the effects and feasibility of using oral tobacco products as both a cessation aid and a method to reduce individual health risk in cigarette smokers. ..
  16. Exploring current smokers? interest in using smokeless tobacco products
    RICHARD J O apos CONNOR; Fiscal Year: 2010
    ..The set of studies may help to tease apart the various aspects of the price-product relationship and so better inform public policy debates. ..
  17. Research Integrity & Financial Conflicts of Interest
    Patricia Tereskerz; Fiscal Year: 2004
    ..4) Explore the utility of using data reduction techniques and appropriate, multi-variate modeling techniques to show which types of financial arrangements predict questionable integrity practices. ..
  18. Interventions for Tobacco Dependent Adolescents
    Dorothy Hatsukami; Fiscal Year: 2005
    ....
  19. Influence of Calorie Labeling on Food Choice
    Brian Elbel; Fiscal Year: 2010
    ..Moreover, it will shed light on why the policy is effective or not. The long term goal is to build on this knowledge to develop effective public polices to combat obesity. ..
  20. Evaluating Low Ignition Propensity Cigarette Legislation
    RICHARD O CONNOR; Fiscal Year: 2009
    ..Taken together, these studies comprise a comprehensive evaluation of the potential impacts of this harm-reduction policy, which will inform policymakers in other jurisdictions considering similar regulations. ..
  21. Novel Determinants and Measures of Smokeless Tobacco Use
    Dorothy K Hatsukami; Fiscal Year: 2010
    ..This study would demonstrate the feasibility and impact of switching ST users to less toxic ST products. Together, these studies will help to guide important policy decisions to reduce the toll of tobacco-related disease. ..
  22. Clinical Supervision and Turnover in Substance Abuse Tx
    Lillian T Eby; Fiscal Year: 2010
    ..This project responds to program announcement PA-03-011 "Services Research in the National Drug Abuse CTN". Substance abuse treatment centers that are affiliated with the Clinical Trails Network will provide data for the project. ..
  23. Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers
    Dorothy Hatsukami; Fiscal Year: 2009
    ..The results from these studies will help determine the effects and feasibility of using oral tobacco products as both a cessation aid and a method to reduce individual health risk in cigarette smokers. ..
  24. Innovative Interventions for Smoking Cessation
    Dorothy Hatsukami; Fiscal Year: 2009
    ..The results of this study will provide useful information on directions to pursue to improve our pharmacotherapies and behavioral treatments and to better understand the various aspects of addiction. ..
  25. National Black Leadership Conference on Genetics
    Kathy Hudson; Fiscal Year: 2004
    ..The Conference will be held in Washington DC in May 2004. ..
  26. NEWBORN GENETIC SCREENING:FOR WHOSE BENEFIT?
    Lainie Ross; Fiscal Year: 2005
    ..OUTCOMES: The major outcomes will be a series of peer-reviewed articles and a full-length book entitled Newborn Genetic Screening: In whose Interest? For whose Benefit? ..
  27. Making Every Voice Count: Public Consultation on Genetics, Environment and Health
    Joan Scott; Fiscal Year: 2007
    ....
  28. Impact of Poor Health & AIDS on Small Businesses in SA
    Mark Pauly; Fiscal Year: 2003
    ..They will be useful for predicting the effect of changes in health on economic activity in this sector, and for allocating resources for disease prevention and treatment. ..
  29. Making Every Voice Count: Public Consultation on Genetics, Environment and Health
    Kathy Hudson; Fiscal Year: 2007
    ..abstract_text> ..
  30. The Effect of Aflatoxin Regulation on Global Liver Cancer Risk
    Felicia Wu; Fiscal Year: 2010
    ..While we focus on the impact of a harmonized aflatoxin standard on global liver cancer burden, the methodologies can be broadened to address standard-setting of other important carcinogens. ..
  31. Engineering of Vascularized Bone
    Jeremy J Mao; Fiscal Year: 2010
    ....
  32. Suicidality in Schizophrenia: Risk & Protective Factors
    DEQUINCY LEZINE; Fiscal Year: 2004
    ..abstract_text> ..
  33. State Policies and Hospitalizations from Nursing Homes
    Vincent Mor; Fiscal Year: 2004
    ..These theoretical insights will help shape the policy implications emerging from the study. ..
  34. Tracking stem cells in engineered tissue and organs in vivo and in real time
    Jeremy J Mao; Fiscal Year: 2010
    ..It also has a potential to contribute to our understanding of the engineered osteochondral interface that is of critical value in bioengineered replacement of arthritic joints. ..
  35. Environmental Epidemiology in Community Settings
    David Ozonoff; Fiscal Year: 2007
    ..It also includes activities to enrich the experience of the trainees and promote social and professional cohesion. ..
  36. Stem Cell Based Soft Tissue Reconstruction
    Jeremy Mao; Fiscal Year: 2009
    ..An interdisciplinary team of biomedical engineers, biologists, biomaterial scientists, imaging scientists and surgical consultants have been assembled to meet the challenges of realizing our goals. ..
  37. SYNERGY OF HOST DEFENSE MECHANISMS IN LUNG
    Arturo Casadevall; Fiscal Year: 2006
    ..By comparing the immune response in Ab-permissive and Ab-non-permissive murine strains we will learn the conditions and mechanisms by which Ab-mediates protection against C. neoformans. ..
  38. Annotating functional sites in 3D biological structures
    RUSS BIAGIO ALTMAN; Fiscal Year: 2010
    ..In particular, we will focus our new capabilities on three difficult function annotation challenges: ATP binding sites, phosphorylation sites, and metabolizing enzyme active sites. ..
  39. Providers' perceptions of the diaphragm in Southern Afr*
    Cynthia Harper; Fiscal Year: 2005
    ..As the diaphragm effectiveness results become available, data from this proposed study will position us to design counseling interventions and to address provider education and training needs. ..
  40. NATIONAL RESEARCH SERVICE AWARD
    Vincent Mor; Fiscal Year: 2007
    ....
  41. Community VOICES (2):Community VOICES on informed consent in emergency situations
    Lynne D Richardson; Fiscal Year: 2010
    ..The entire toolkit will be made publicly available on the Mount Sinai EM website and will be actively disseminated to medical societies, governmental agencies, bioethics organizations &others. ..
  42. Stem-Cell Based Tissue Engineering in Regenerative Medicine Conference
    Jeremy Mao; Fiscal Year: 2006
    ..abstract_text> ..
  43. LONGITUDINAL ORAL HEALTH OUTCOMES IN HIGH-RISK ADULTS
    GREGG GILBERT; Fiscal Year: 2003
    ....
  44. SITE-SPECIFIC MUTAGENESIS OF ISOMERASES
    Gregory Petsko; Fiscal Year: 1990
    ..Finally, mutations will be made at several other positions where the crystallographic results and sequence conservation imply a possible role in either active site architecture or catalysis: Ser 96, Cys 126, Glu 97, and Asn 10...
  45. ERYTHROCYTAPHERESIS TO LOWER IRON LOADING IN THALASSEMIA
    Alan Cohen; Fiscal Year: 2002
    ....
  46. OUTCOMES OF HOSPITAL STAFFING
    Linda Aiken; Fiscal Year: 1999
    ....
  47. Effects of Dioxin on Vietnamese Civilians
    David Carpenter; Fiscal Year: 2004
    ..7. ..
  48. ARE FEDERAL REGULATIONS ON ALCOHOL USE SAFE
    Jonathan Howland; Fiscal Year: 2001
    ..The results of this study will provide information on the risks of hangovers for injury and may inform public policy on alcohol use in conjunction with commercial ship operation. ..
  49. FREE PLASMA SEX HORMONE AND ANDROGEN ACTION
    Robert Rosenfield; Fiscal Year: 1980
    ..The hypothesis that LH is insensitive to modest decrements of plasma testosterone will be tested by acutely lowering plasma testosterone levels in normal volunteers with aminoglutethimide...